Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma

Autophagy

Volumn 10, Issue 8, 2014, Pages 1415-1425

  Barnard, Rebecca A ^a   Wittenburg, Luke A ^a   Amaravadi, Ravi K ^b   Gustafson, Daniel L ^a   Thorburn, Andrew ^c   Thamm, Douglas H ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Autophagy; Canine model; Doxorubicin; Hydroxychloroquine; Lymphoma

Indexed keywords

DOXORUBICIN; HYDROXYCHLOROQUINE; MICROTUBULE ASSOCIATED PROTEIN 1; ANTINEOPLASTIC AGENT;

ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DOG; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL SYMPTOM; LETHARGY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANIMAL; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; LYMPHOMA; PET ANIMAL; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; VETERINARY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HYDROXYCHLOROQUINE; LYMPHOMA; MALE; PETS; TREATMENT OUTCOME;

EID: 84905826586     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.29165     Document Type: Article

References (55)

1. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140:313-26; PMID:20144757; http://dx.doi.org/10.1016/j. cell.2010.01.028
2. Ichimura Y, Komatsu M. Pathophysiological role of autophagy: lesson from autophagy-deficient mouse models. Exp Anim 2011; 60:329-45; PMID:21791873; http://dx.doi.org/10.1538/ expanim.60.329
3. Suraweera A, Münch C, Hanssum A, Bertolotti A. Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell 2012; 48:242-53; PMID:22959274; http://dx.doi. org/10.1016/j.molcel.2012.08.003
4. Kaushik S, Rodriguez-Navarro JA, Arias E, Kiffin R, Sahu S, Schwartz GJ, Cuervo AM, Singh R. Autophagy in hypothalamic AgRP neurons regulates food intake and energy balance. Cell Metab 2011; 14:173-83; PMID:21803288; http://dx.doi. org/10.1016/j.cmet.2011.06.008
5. Fujiwara Y, Kikuchi H, Aizawa S, Furuta A, Hatanaka Y, Konya C, Uchida K, Wada K, Kabuta T. Direct uptake and degradation of DNA by lysosomes. Autophagy 2013; 9:1167-71; PMID:23839276; http://dx.doi.org/10.4161/auto.24880
6. Loos B, Engelbrecht AM, Lockshin RA, Klionsky DJ, Zakeri Z. The variability of autophagy and cell death susceptibility: Unanswered questions. Autophagy 2013; 9:1270-85; PMID:23846383; http://dx.doi. org/10.4161/auto.25560
7. Jin S, White E. Role of autophagy in cancer: management of metabolic stress. Autophagy 2007; 3:28-31; PMID:16969128
8. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117:326-36; PMID:17235397; http://dx.doi.org/10.1172/JCI28833
9. Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O'Dwyer PJ. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res 2013; 19:2995-3007; PMID:23461901; http://dx.doi.org/ 10.1158/1078-0432.CCR-12-1542
10. Ding ZB, Hui B, Shi YH, Zhou J, Peng YF, Gu CY, Yang H, Shi GM, Ke AW, Wang XY, et al. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Clin Cancer Res 2011; 17:6229-38; PMID:21825039; http://dx.doi.org/10.1158/1078-0432.CCR- 11-0816
11. Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 2013; 73:3-7; PMID:23288916; http://dx.doi.org/10.1158/0008-5472.CAN-12-2464
12. Ni HM, Bockus A, Boggess N, Jaeschke H, Ding WX. Activation of autophagy protects against acetaminophen-induced hepatotoxicity. Hepatology 2012; 55:222-32; PMID:21932416; http://dx.doi.org/10.1002/hep.24690
13. Cabrera S, Fernández AF, Mariño G, Aguirre A, Suárez MF, Español Y, Vega JA, Laurà R, Fueyo A, Fernández- García MS, et al. ATG4B/autophagin-1 regulates intestinal homeostasis and protects mice from experimental colitis. Autophagy 2013; 9:1188-200; PMID:23782979; http://dx.doi.org/10.4161/ auto.24797
14. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115:2679-88; PMID:16200202; http://dx.doi.org/10.1172/ JCI26390
15. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomideinduced cytotoxicity for malignant glioma cells. Cell Death Differ 2004; 11:448-57; PMID:14713959; http://dx.doi.org/10.1038/sj.cdd. 4401359
16. Bristol ML, Emery SM, Maycotte P, Thorburn A, Chakradeo S, Gewirtz DA. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther 2013; 344:544-52; PMID:23291713; http://dx.doi.org/10.1124/ jpet.112.199802
17. Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, Kim TS, Choi JS, Jang IJ, Park JW. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother 2009; 53:1468-75; PMID:19188392; http://dx.doi. org/10.1128/AAC.00339-08
18. Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 2003; 25:671-81; PMID:14639053; http://dx.doi. org/10.1097/00007691-200312000-00005
19. Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993; 25:392-407; PMID:7904547; http://dx.doi. org/10.2165/00003088-199325050-00005
20. Oberkirchner U, Linder KE, Olivry T. Successful treatment of a novel generalized variant of canine discoid lupus erythematosus with oral hydroxychloroquine. Vet Dermatol 2012; 23:65- 70, e15-6; PMID:21718370; http://dx.doi. org/10.1111/j.1365-3164.2011.00994.x
21. Mauldin EA, Morris DO, Brown DC, Casal ML. Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment. Vet Dermatol 2010; 21:373-82; PMID:20374572
22. McChesney EWMA. Laboratory Studies of the 4-aminoquinoline antimalarials: I. Some biochemical characteristics of chloroquine, hydroxychloroquine, and SN-7718. Antibiot Chemother 1961; 11:800-10
23. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004; 40:858- 80; PMID:15120042; http://dx.doi.org/10.1016/j. ejca.2003.11.031
24. Kimmelman J, Nalbantoglu J. Faithful companions: a proposal for neurooncology trials in pet dogs. Cancer Res 2007; 67:4541-4; PMID:17510377; http:// dx.doi.org/10.1158/0008-5472.CAN-06-3792
25. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4:1567-71; PMID:9626479
26. Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 2005; 11:4827-34; PMID:16000580; http://dx.doi. org/10.1158/1078-0432.CCR- 04-2510
27. Paoloni MCTA, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 2009; 4:e4972; PMID:19330034; http://dx.doi.org/10.1371/journal. pone.0004972
28. Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin Cancer Res 2009; 15:3503-10; PMID:19417014; http://dx.doi.org/10.1158/1078-0432.CCR-08-3113
29. Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ 3rd, Kraft SL, Gustafson DL, Vail DM. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation. Clin Cancer Res 2010; 16:1498-508; PMID:20160058; http://dx.doi.org/10.1158/1078-0432.CCR-09-2804
30. Wittenburg LA, Gustafson DL, Thamm DH. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res 2010; 16:4832-42; PMID:20705615; http://dx.doi. org/10.1158/1078-0432.CCR-10-1238
31. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. The Bruton tyrosine kinase inhibitor PCI- 32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107:13075- 80; PMID:20615965; http://dx.doi.org/10.1073/ pnas.1004594107
32. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003; 9:2755-68; PMID:12855656
33. Thomas R, Seiser EL, Motsinger-Reif A, Borst L, Valli VE, Kelley K, Suter SE, Argyle D, Burgess K, Bell J, et al. Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leuk Lymphoma 2011; 52:1321-35; PMID:21375435; http://dx.doi.org/10.3109/10428194.2011.559802
34. Hartmann EM, Ott G, Rosenwald A. Molecular biology and genetics of lymphomas. Hematol Oncol Clin North Am 2008; 22:807-23, vii; PMID:18954738; http://dx.doi.org/10.1016/j.hoc.2008.07.004
35. Fosmire SP, Thomas R, Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Smith TL, Gardner LA, Ritt MG, Bell JS, et al. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. Vet Pathol 2007; 44:467-78; PMID:17606508; http://dx.doi. org/10.1354/vp.44-4-467
36. Zettl A, Rüdiger T, Konrad MA, Chott A, Simonitsch- Klupp I, Sonnen R, Müller-Hermelink HK, Ott G. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004; 164:1837-48; PMID:15111330; http://dx.doi.org/10.1016/S0002-9440(10)63742-X
37. Shaknovich R, Melnick A. Epigenetics and B-cell lymphoma. Curr Opin Hematol 2011; 18:293- 9; PMID:21577103; http://dx.doi.org/10.1097/ MOH.0b013e32834788cf
38. Bryan JN, Jabbes M, Berent LM, Arthur GL, Taylor KH, Rissetto KC, Henry CJ, Rahmatpanah F, Rankin WV, Villamil JA, et al. Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphoma. BMC Genet 2009; 10:73; PMID:19912643; http://dx.doi. org/10.1186/1471-2156-10-73
39. Vail DM, Young KM. Canine lymphoma and lymphoid leukemia. In: Withrow SJ, and Vail D M, ed. Withrow and MacEwen's Small Animal Clinical Oncology. St. Louis: WB Saunders, 2007:699-712
40. Jacobs RM. MJB, Valli V E. Tumors of the hemolymphatic system. In: D M, ed. Tumors in Domestic Animals. Ames, IA: Iowa State Press, 2002:119-98
41. Lori JC, Stein TJ, Thamm DH. Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study. Vet Comp Oncol 2010; 8:188-95; PMID:20691026
42. Postorino NCSJ, Withrow SJ. Single agent therapy with Adriamycin for canine lymphosarcoma. J Am Anim Hosp Assoc 1989; 24:221-5 (Pubitemid 19085754)
43. Valerius KD, Ogilvie GK, Mallinckrodt CH, Getzy DM. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 1997; 210:512-6; PMID:9040837
44. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004; 27:257-64; PMID:15500562; http://dx.doi. org/10.1111/j.1365-2885. 2004.00607.x
45. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47; PMID:19097774; http://dx.doi.org/10.1016/j. ejca.2008.10.026
46. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 2002; 91:1488- 501; PMID:12115848; http://dx.doi.org/10.1002/ jps.10161
47. Selting KA, Ogilvie GK, Gustafson DL, Long ME, Lana SE, Walton JA, Hansen RA, Turner AS, Laible I, Fettman MJ. Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Am J Vet Res 2006; 67:145-51; PMID:16426224; http://dx.doi. org/10.2460/ajvr.67.1.145
48. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445- 544; PMID:22966490; http://dx.doi.org/10.4161/ auto.19496
49. Omodeo-Salè F, Cortelezzi L, Basilico N, Casagrande M, Sparatore A, Taramelli D. Novel antimalarial aminoquinolines: heme binding and effects on normal or Plasmodium falciparum-parasitized human erythrocytes. Antimicrob Agents Chemother 2009; 53:4339-44; PMID:19651905; http://dx.doi. org/10.1128/AAC.00536-09
50. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 1359-68; PMID:24991840; http://dx.doi. org/10.4161/auto.28984
51. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, et al. Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/ refractory myeloma. Autophagy 2014; 1380-90; PMID:24991834; http://dx.doi.org/10.4161/ auto.29264
52. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 1369-79; PMID:24991839; http://dx.doi.org/10.4161/ auto.29118
53. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian J, Troxel AB, et al. Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 1391- 1402; PMID:24991838; http://dx.doi.org/10.4161/ auto.29119
54. Veterinary Co-operative Oncology Group (VCOG). Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOGCTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004; 2:195-213; PMID:19379294; http:// dx.doi.org/10.1111/j.1476-5810.2004.0053b.x
55. Wittenburg LA, Thamm DH, Gustafson DL. Development of a limited-sampling model for prediction of doxorubicin exposure in dogs. Vet Comp Oncol 2014; 12:114-9; PMID:22747489; http://dx.doi.org/10.1111/j.1476-5829.2012.00340.x